

Jagannadha Avasarala

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3507410/publications.pdf>

Version: 2024-02-01

32
papers

234
citations

1306789

7
h-index

996533

15
g-index

39
all docs

39
docs citations

39
times ranked

284
citing authors

#	ARTICLE	IF	CITATIONS
1	Bupropion seizure proportion among new-onset generalized seizures and drug related seizures presenting to an emergency department. <i>Journal of Emergency Medicine</i> , 2002, 22, 235-239.	0.3	96
2	Inadequacy of Clinical Trial Designs and Data to Control for the Confounding Impact of Race/Ethnicity in Response to Treatment in Multiple Sclerosis. <i>JAMA Neurology</i> , 2014, 71, 943.	4.5	24
3	The TOUCH program and natalizumab: Fundamental flaw in patient protection. <i>F1000Research</i> , 2015, 4, 1450.	0.8	12
4	Letter by Avasarala Regarding Article, "2015 AHA/ASA Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association" <i>Stroke</i> , 2015, 46, e234.	1.0	10
5	Use of anti-TNF- α therapy in Crohn's disease is associated with increased incidence of multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 51, 102942.	0.9	10
6	Redefining Acute Relapses in Multiple Sclerosis: Implications for Phase 3 Clinical Trials and Treatment Algorithms. <i>Innovations in Clinical Neuroscience</i> , 2017, 14, 38-40.	0.1	9
7	It's Time For Combination Therapies: in Multiple Sclerosis. <i>Innovations in Clinical Neuroscience</i> , 2017, 14, 28-30.	0.1	9
8	FDA-approved drugs for multiple sclerosis have no efficacy or disability data in non-Caucasian patients. <i>CNS Spectrums</i> , 2019, 24, 279-280.	0.7	8
9	The TOUCH program and natalizumab: Fundamental flaw in patient protection. <i>F1000Research</i> , 2015, 4, 1450.	0.8	8
10	Vitamin D deficiency in multiple sclerosis: Should testing and treatment be based on racial background?. <i>Journal of the Neurological Sciences</i> , 2015, 358, 417-418.	0.3	7
11	Is a Neurologist Needed to Diagnose Acute Stroke in the Emergency Department?. <i>JAMA Neurology</i> , 2016, 73, 1273.	4.5	7
12	Anti-MOG and Anti-AQP4 positive neuromyelitis optica spectrum disorder in a patient with myasthenia gravis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102205.	0.9	6
13	Eculizumab package insert recommendations for meningococcal vaccinations: call for clarity and a targeted approach for use of the drug in neuromyelitis optica spectrum disorder. <i>CNS Spectrums</i> , 2021, 26, 185-187.	0.7	5
14	Clinically isolated syndrome " Rethinking the diagnosis. <i>Journal of the Neurological Sciences</i> , 2015, 353, 79-80.	0.3	4
15	VAERS reported new-onset seizures following use of Covid 19 vaccinations as compared to influenza vaccinations. <i>British Journal of Clinical Pharmacology</i> , 0, , .	1.1	4
16	Optimization of acute stroke care in the emergency department: a call for better utilization of healthcare resources amid growing shortage of neurologists in the United States. <i>CNS Spectrums</i> , 2018, 23, 248-250.	0.7	3
17	Can Aspirin Minimize Stroke Risk and New Lesion Formation in Multiple Sclerosis?. <i>Frontiers in Neurology</i> , 2018, 9, 613.	1.1	3
18	Radiologically isolated syndrome is antiquated amidst evolving McDonald criteria for multiple sclerosis. <i>CNS Spectrums</i> , 2021, 26, 307-309.	0.7	2

#	ARTICLE	IF	CITATIONS
19	Can a diagnosis of multiple sclerosis be made without ruling out neuromyelitis optica spectrum disorder?. Multiple Sclerosis and Related Disorders, 2020, 40, 101949.	0.9	2
20	The TOUCH program and natalizumab: Fundamental flaw in patient protection. F1000Research, 0, 4, 1450.	0.8	2
21	Inflammatory trigeminal sensory neuropathy. Neurology, 1997, 49, 308-308.	1.5	1
22	Ventricular Obstruction From Neurocysticercosis. Archives of Neurology, 2005, 62, 1018.	4.9	1
23	Pivotal clinical trial enrollment of Blacks in multiple sclerosis or neuromyelitis spectrum disorder: when will we achieve parity?. CNS Spectrums, 2022, 27, 527-529.	0.7	1
24	Multiple sclerosis in US minority populations: Clinical practice insights. Neurology: Clinical Practice, 2015, 5, 186-187.	0.8	0
25	Diagnosing Lymphomatosis Cerebri. JAMA Neurology, 2015, 72, 1536.	4.5	0
26	Computer-aided Therapeutics in Treating Autoimmune Encephalitis. JAMA Neurology, 2016, 73, 127.	4.5	0
27	Stroke Diagnosis and Treatment in the Emergency Department—Reply. JAMA Neurology, 2017, 74, 362.	4.5	0
28	Standardization of MRI data and disability quantification in the post-EPIC era. CNS Spectrums, 2018, 23, 8-9.	0.7	0
29	Discordant disability data in multiple sclerosis phase 3 studies among sphingosine-1- receptor modulator drugs. Multiple Sclerosis and Related Disorders, 2020, 46, 102529.	0.9	0
30	Clinical suspicion: Improving the odds of survival in rapidly progressive brainstem PRES in neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2020, 45, 102355.	0.9	0
31	Time to Rethink CIS Criteria. Multiple Sclerosis Discovery Forum, 0, , .	0.0	0
32	Antibody panels for autoimmune and paraneoplastic disorders: A pandora's box for clinicians. Multiple Sclerosis and Related Disorders, 2022, 64, 103947.	0.9	0